diabetes mellitus News
-
Regor announces the first patient dosed in the U.S. in the Phase II clinical trial for RGT-075, a novel small molecule GLP-1R agonist
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase II clinical trial of the Company’s novel oral small molecule GLP-1 receptor agonist RGT-075 in the U.S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-characterized class of hypoglycemic ...
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a ...
-
Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesity
BACKGROUND: Pulse wave velocity (PWV) is a marker of arterial stiffness. The aim of the present study was to compare PWV in patients with type 2 diabetes mellitus (T2DM) or obesity and healthy subjects in an outpatient setting. METHODS: A cross-sectional study was conducted in patients with obesity without T2DM (n = 37), T2DM without obesity (n = 40), T2DM plus ...
By Axelife SAS
-
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
/www.w3.org/1999/xhtml">Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no ...
-
Agrochemicals blamed for chronic kidney disease in Sri Lanka
A team of Sri Lankan and WHO scientists has linked the high prevalence of chronic kidney disease of uncertain aetiology (CKDu) on the island to indiscriminate use of agrochemicals including fertilisers and pesticides. In its final report released on February 28, the team, led by WHO researcher Shanthi Mendis, identified districts in the north, centre and east of the island and the rice-growing ...
By SciDev.Net
-
Peptides for Diabetes Research—a Special Offer of BOC Sciences
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
By BOC Sciences
-
Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment
Hitachi, Ltd. (TSE: 6501, Hitachi), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood ...
-
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
Multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE® platform to discover controllable genetic therapies to treat serious diseases Vertex will pay Obsidian up to $75 million in equity, upfront payments and potential research milestones Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Obsidian Therapeutics announced today that the two ...
-
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems. “We believe our novel ultra-small CRISPR systems have the potential ...
-
AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes
AVM Biotechnology, LLC, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) will allow the company to pursue additional research in the use ...
-
BioXcel Therapeutics Announces FDA Approval of IGALMI (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder1 IGALMI demonstrated onset of action as early as 20 minutes and high response rate with both 120 mcg and 180 mcg doses in pivotal studies1 Up to 25 million agitation episodes for these two patient populations in the U.S. annually2-3 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you